ATHENS, Greece, Nov. 13, 2025 (GLOBE NEWSWIRE) — EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes, announced today its results for the three and nine-month periods ended September 30, 2025. Third Quarter 2025 Highlights:Total net revenues for the quarter of $14.4 million.Net loss attributable to controlling shareholders, of $0.7 million or $0.24 loss per share basic and diluted.Adjusted net loss1 attributable to controlling shareholders for the quarter of $0.6 million or $0.23 adjusted loss per share attributable to controlling shareholders basic and diluted.Adjusted EBITDA1 for the quarter was $4.1 million.An average of 12.0 vessels were owned and operated during the third quarter of 2025 earning an average time...

OMAHA, Neb., Nov. 13, 2025 (GLOBE NEWSWIRE) — CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”), today announced its financial results for the fiscal first quarter ended September 30, 2025 (“Q1 2026”), and is providing an update on its DOGE treasury strategy. “During the fiscal first quarter 2026 we executed on our vision to establish the world’s first Dogecoin Treasury,” said Clayton Adams, Chief Executive Officer of CleanCore. “We have continued to grow our DOGE holdings in a disciplined manner as we advance toward our longer-term objective of acquiring up to 5% of Dogecoin’s circulating supply. Beyond accumulation, our focus has been on expanding Dogecoin’s real-world utility through payments, remittances, and integrations within the global sports and entertainment ecosystem. We believe that...

New platform converts an established lead-generation system into a scalable intake and data monetization engine targeting the underserved and subprime consumer market. Proven legacy software reengineered from SurgePays’ legacy LogicsIQ system BARTLETT, Tenn., Nov. 13, 2025 (GLOBE NEWSWIRE) — SurgePays, Inc. (NASDAQ: SURG), a wireless and fintech technology company connecting subprime and underserved consumers to essential mobile and financial services, today announced the next phase of its data monetization strategy with the launch of ProgramBenefits.com, a SurgePays platform developed to convert verified benefit-qualified consumers into measurable, recurring revenue opportunities. Previously, the Company announced the launch of its new Growth Marketing and Data Partnerships Division to transform its expanding consumer data ecosystem...

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival (DFS), independent of radiation therapy modality utilized                                                         Company plans to initiate pivotal phase 3 clinical trial of CAN-2409 in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) and progressive disease, despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026 Announced encouraging updated survival data for patients enrolled in its phase 1b clinical trial of CAN-3110 (linoserpaturev) in recurrent high-grade glioma (rHGG) Manuscript published in the scientific journal Science Translational Medicine, reporting the...

Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply, development, and license agreement with leading medical-surgical product manufacturer and distributor Medline LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) — Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates. “Our first weeks as a public company have been extremely productive, and our continued execution brings us closer to achieving our immediate strategic goal of developing a portfolio of potential best-in-class products...

Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4)Released material under the Company’s Specials license for a second rare pediatric ophthalmology condition caused by mutations in BBS10, with the prescribing physician treating the first patient during the quarter. The BBS10 program has been awarded Rare Pediatric Disease Designation (RPDD)LONDON and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2025,...

BALLERUP, Denmark, Nov. 13, 2025 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech”), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the third quarter of 2025 for the period ended September 30, 2025. Recent Financial HighlightsQ3 2025 revenue of $3.8 million, an increase of 54% increase from $2.5 million in Q3 2024. Strong gross profit margins improvement (+28.1% points) and operating expense reduction (down 12.6%) highlight operational efficiencies. Q3 2025 net loss of $(1.5) million compared to $(2.8) million in Q3 2024. Ending cash balance of $7.3 million on September 30, 2025.OutlookQ4 2025 revenue expected to be between $4.6 and $5.6 million, equating to 38% to 67% growth compared to Q4...

Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate’s New Drug Application (NDA) for CTx-1301 (dexmethylphenidate HCl), a once-daily, extended-release therapy designed to optimize ADHD treatment. The FDA assigned...

Announced U.S. Food and Drug Administration (FDA) Acceptance for Reviewof New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Neurocritical Care Annual Meeting Granted Sixth U.S. Patent Covering IV Dosing Regimen for GTx-104 PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights...

WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On September 14-15, 2025, the Company presented new data on the long-term neurological efficacy and safety of ALXN1840 (tiomolybdate choline) at the 150th American Neurological Association (ANA) Annual Meeting. Matthew Lorincz, M.D., Ph.D., Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the University of Michigan delivered the poster and oral presentations. The new findings presented at ANA highlight the long-term neurological benefit of...